BLT-Immune Humanized Mice as a Model for Nivolumab-Induced Immune-Mediated Adverse Events: Comparison of the NOG and NOG-EXL Strains
- 8 March 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Toxicological Sciences
- Vol. 169 (1), 194-208
- https://doi.org/10.1093/toxsci/kfz045
Abstract
Checkpoint inhibitors represent a new class of therapeutics in the treatment of cancer that has demonstrated remarkable clinical effectiveness. However, some patients have experienced serious immune-mediated adverse effects including pneumonitis, hepatitis, colitis, nephritis, dermatitis, encephalitis, and adrenal or pituitary insufficiency. These adverse events were not predicted by nonclinical studies. To determine if bone marrow-liver-thymus (BLT) immune humanized mice could demonstrate these adverse effects, we studied the effect of nivolumab on 2 strains of BLT-humanized mice, NOD.Cg-Prkdcscid Il2rgtm1Sug/JicTac (NOG) and NOD.Cg-Prkdcscid Il2rgtm1Sug Tg(SV40/HTLV-IL3, CSF2)10-7Jic/JicTac (NOG-EXL). Mice were treated with 2.5, 5.0, or 10.0 mg/kg nivolumab or saline twice weekly for 28 days. BLT-NOG mice had significantly reduced survival compared with BLT-NOG-EXL mice. In spite of the difference in survival, both BLT-humanized strains showed adverse reactions similar to those reported in humans, including pneumonitis and hepatitis, with nephritis, dermatitis and adrenalitis also noted in some individuals. Additional histopathologic findings included pancreatic atrophy, myositis, and osteomyelitis in some animals. T-cell activation increased with concomitant loss of PD-1 detection. These findings show that BLT immune humanized mice can demonstrate immune-mediated adverse effects of antiPD1 therapy, and may represent a model that can be used to better understand toxicity of this class of drugs.Keywords
Funding Information
- FDA
This publication has 34 references indexed in Scilit:
- PD-1 Blockade in Chronically HIV-1-Infected Humanized Mice Suppresses Viral LoadsPLOS ONE, 2013
- Establishment of a Human Allergy Model Using Human IL-3/GM-CSF–Transgenic NOG MicePublished by The American Association of Immunologists ,2013
- Graft versus Host Disease in the Bone Marrow, Liver and Thymus Humanized Mouse ModelPLOS ONE, 2012
- Programmed death-1 is required for systemic self-tolerance in newly generated T cells during the establishment of immune homeostasisJournal of Autoimmunity, 2011
- PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceThe Journal of Experimental Medicine, 2011
- Highly Sensitive Model for Xenogenic GVHD Using Severe Immunodeficient NOG MiceTransplantation, 2009
- Adaptive immunity maintains occult cancer in an equilibrium stateNature, 2007
- NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cellsBlood, 2002
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Anti-SCID mouse reactivity shapes the human CD4+ T cell repertoire in hu-PBL-SCID chimeras.The Journal of Experimental Medicine, 1994